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OBJECTIVES To evaluate recent trends, we examined longitudinal national data on the outpatient use of
warfarin in atrial fibrillation (AF), beta-blockers and aspirin in coronary artery disease
(CAD), and angiotensin-converting enzyme inhibitors (ACEIs) in congestive heart failure
(CHF).
BACKGROUND Previous studies indicate that specific cardiac medications are underutilized.
METHODS We used the National Disease and Therapeutic Index (NDTI) (produced by IMS
HEALTH, Plymouth Meeting, Pennsylvania) for 1990 to 2002, and the National Ambu-
latory Medical Care Surveys (NAMCS) for 1990 to 2000 to follow nationally representative
samples of outpatient visits. For visits by patients with AF (total n  14,634 visits), CAD
(n  35,295), and CHF (n  33,008), we examined trends in the proportion of visits with
the selected medications reported.
RESULTS Warfarin use in AF increased from 12% in 1990, to 41% in 1995, to 58% in 2001 in NDTI;
a similar moderation of recent increase was seen in NAMCS. For CAD in NDTI,
beta-blocker use increased slowly from 19% in 1990, to 20% in 1995, then to 40% in 2001;
NAMCS showed this same pattern. Aspirin use in CAD in NDTI increased from 18% in
1990, to 19% in 1995, to 38% in 2001; NAMCS, however, showed lower use rates. For
NDTI, ACEI use in CHF increased from 24% in 1990 to 36% in 1996, but increased to only
39% by 2001, a general pattern also seen in NAMCS.
CONCLUSIONS Both national datasets demonstrate continuing underutilization of these cardiac medications
of proven benefit. Although use is increasing, it remains lower than expected, and some
increases noted in earlier years have slowed. Substantial public health benefits would result
from further adoption of these effective therapies. (J Am Coll Cardiol 2003;41:56–61)
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Despite the considerable investment in developing
evidence-based clinical treatment guidelines for cardiac
disease, recommended cardiac medications may not always
be used when appropriate (1–5). Substantial consensus has
been developed through randomized clinical trials and
population studies about the use of warfarin in the manage-
ment of atrial fibrillation (AF), angiotensin-converting en-
zyme inhibitors (ACEIs) (including angiotensin receptor
See page 69
blockers) in congestive heart failure (CHF), and beta-
blockers and aspirin in coronary artery disease (CAD).
Underutilization of these medications unnecessarily in-
creases the risk of adverse outcomes for patients with these
prevalent conditions.
Atrial fibrillation is a leading cause of stroke and the most
prevalent chronic cardiac rhythm disorder, affecting 4% of
the population older than 60 years (6). Six randomized
controlled trials conducted between 1989 and 1994 demon-
strated that long-term anticoagulation with warfarin can
safely reduce the risk of stroke attributable to AF (7,8).
Despite evidence of benefit and several resulting expert
recommendations, the diffusion of warfarin use into practice
has been slow and incomplete. As of the mid-1990s,
warfarin use was reported in 40% of patients with AF for
whom it appeared to be an appropriate therapy (1,9).
Congestive heart failure is a common clinical end stage
for several cardiovascular diseases including CAD, hyper-
tension, cardiomyopathy, and valvular disease. Recom-
mended management of CHF has changed dramatically
over the past decade. Evidence of reduced mortality from
randomized clinical trials and the development of subse-
quent professional evidence-based guidelines have estab-
lished ACEIs as the first-line medication therapy in the
treatment of CHF (10,11). While past studies show a
gradual increase in the use of ACEIs through the 1990s,
these increases have been limited, and less than half of
eligible patients are taking ACEIs (5,12). Utilization of this
class of medications remains low (5,10,12–14), particularly
among family physicians (15).
Coronary artery disease is the most prevalent cardiac
disorder, affecting over 12 million in the U.S. It is estimated
that each year over one million individuals in the U.S. suffer
a coronary event (either myocardial infarction or sudden
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cardiac death) (16). Randomized clinical trials have shown
that beta-blockers reduce the risk of mortality after myo-
cardial infarction, reduce ischemic events in patients with
mildly symptomatic disease, and improve survival when
compared with diuretics (17). Population studies, aug-
mented by clinical trials results, have demonstrated the
benefits of aspirin therapy, particular after acute coronary
syndromes (17,18). Both beta-blockers and aspirin appear
to have tremendous long-term benefits in secondary
prevention (19,20). Past assessments have shown that
aspirin and beta-blockers are underused in CAD, despite
their clinically proven benefits and cost-effectiveness
(3,4,18,19,21–28). When used to treat myocardial infarc-
tion, beta-blocker usage increased steadily until 1994, when
it reached steady state usage near 60% (21). Similarly,
aspirin use has increased over time although utilization
remains low, perhaps as low as a quarter of outpatients with
CAD in 1996 (23).
We analyzed two ongoing national surveys of office-based
physicians’ prescribing patterns to track recent longitudinal
patterns in the use of cardiac medication therapies of proven
benefit. Using information available from the federal Na-
tional Ambulatory Medical Care Surveys (NAMCS) and
the National Disease and Therapeutic Index (NDTI) pro-
duced by IMS HEALTH (Plymouth Meeting, Pennsylva-
nia), we provide a national update of recommended cardiac
medication use in an outpatient setting.
METHODS
Data sources. Data for this study were obtained from two
sources of longitudinal national data on physician prescrib-
ing practices: NAMCS for 1990 through 2000 (29) and
NDTI for 1990 through the first quarter of 2002 (30).
The NAMCS is a continuing survey conducted annually
by the National Center for Health Statistics that provides
ongoing nationally representative diagnostic and prescribing
information on U.S. office-based physicians and their pa-
tients. Physicians from the master lists of the American
Medical Association and the American Osteopathic Asso-
ciation (both in Chicago, Illinois) are selected by random
stratified sampling by specialty and geographic region.
Nonpatient care specialties, most notably anesthesiology,
pathology, and radiology, are excluded. For each participat-
ing physician in each year, one week is randomly selected
and visits during this week systematically sampled. Non-
office contacts, such as phone or institutional encounters, are
excluded.
Physicians completed encounter forms detailing clinical
interactions, up to six continuing and newly ordered med-
ication therapies (including over-the-counter and self-
medication), patient demographic information, and diagno-
sis information coded into International Classification of
Disease Codes, 9th revision, Clinical Modification (ICD-
9-CM) (31) and NAMCS-specific reason-for-visit codes.
For each visit record, the National Center for Health
Statistics calculates a visit weight using physician and visit
sampling rates adjusted for nonresponse. Visit weights can
be used to extrapolate to national practice patterns for
office-based physicians.
The NDTI is an ongoing survey of U.S. office-based
physicians conducted by IMS HEALTH providing nation-
ally representative diagnostic and treatment data (32). Like
NAMCS, physicians from the American Medical Associa-
tion and the American Osteopathic Association master lists
are randomly sampled by region and specialty. Once an
adequate sampling panel has been established, at least 3,500
participating physicians are sampled quarterly by region and
specialty. Physicians are permitted to remain in the sample
as long as they wish, with replacements selected for attri-
tion.
Each quarter, physicians participating in NDTI report on
each patient encounter during a randomly selected, consec-
utive, two-workday sampling period. They record informa-
tion detailing patient diagnosis, prescribed and known
over-the-counter medication therapies, and demographic
information. Patient contacts are largely comprised of office
visits (85% in 2000), but also include hospital (10%) and
nursing home (1%) visits, as well as telephone contacts (3%).
Each encounter can generate multiple, separate data records
for each physician-reported diagnosis. Because we have used
summary tabular data available from NDTI, we were not
able to account for medication contraindications.
For both data sources, ICD-9-CM codes were used to
classify patients with AF, CHF, and CAD (31). Atrial
fibrillation was identified by ICD-9-CM diagnostic code
427.3 (excluding 427.32 for NAMCS). Congestive heart
failure was identified by ICD-9-CM codes 398.91, 402.01,
402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91,
404.93, and 428. Coronary artery disease was identified
using ICD-9-CM codes 413.0, 413.9, 414.0, 414.2, 414.5,
414.8, and 414.9. Some NAMCS visits were excluded
because of the presence of additional diagnoses that repre-
sent relatively strong contraindications for the medications
under consideration. For warfarin use, we excluded AF
patients with peptic ulcer disease, gastritis, duodenitis,
alcoholism, gait abnormality, ataxia, Alzheimer’s or other
dementia, cerebral hemorrhage, seizure disorder, benign or
malignant central nervous system tumors, and renal insuf-
ficiency. In assessing ACEI use in CHF, we excluded
hyperkalemia. Two separate samples were formed among
Abbreviations and Acronyms
ACEI  angiotensin-converting enzyme inhibitor
AF  atrial fibrillation
CAD  coronary artery disease
CHF  congestive heart failure
ICD-9-CM  International Classification of Disease
Codes, 9th revision, Clinical Modification
NAMCS  National Ambulatory Medical Care
Survey
NDTI  National Disease and Therapeutic Index
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CAD patients: for aspirin, we excluded peptic ulcer disease,
gastritis, duodenitis, and cerebral hemorrhage, while for
beta-blockers we excluded bronchospasm, chronic obstruc-
tive pulmonary disease, asthma, cardiac conduction blocks,
and peripheral vascular disease.
Medications were defined using NAMCS-specific drug
codes and by generic and proprietary names in NDTI.
Warfarin use was defined to include other anticoagulants,
including heparin. Aspirin use was identified in patients
prescribed single-ingredient aspirin formulations, combina-
tion drugs containing aspirin (excluding those medications
indicated for acute analgesia), various antiplatelet aspirin
alternatives such as ticlopidine and clopidogrel, and antico-
agulants. Beta-blockers were defined as all beta-blockers
available as single or combination products and included
alpha-beta-blockers. Angiotensin-converting enzyme in-
hibitor use included all ACEIs, as well as angiotensin II
receptor blockers.
For the 11 years of study under NAMCS, 1,532 patient
visits were recorded for AF, 3,113 for CHF, 7,977 for CAD
with beta-blockers, and 7,700 for CAD with aspirin. The
NDTI provided much larger sample sizes. For the 13 years
of study, NDTI provided data on 16,138 patient visits for
AF, 29,727 for CHF, and 65,194 for CAD.
Statistical analysis. Our analysis focused on estimating the
rate of warfarin used for AF, ACEIs used for CHF, and
beta-blockers and aspirin used for CAD by U.S. office-
based physicians. Patients receiving one or more of the
selected medications were identified on the basis of the
coding of the generic or proprietary names of each medica-
tion in each drug class among as many as six possible
medication codes for NAMCS and an unlimited number
for NDTI for each visit. For both NAMCS and NDTI, our
outcome measure was the proportion of visits where the use
of the selected medications was reported.
For both NAMCS and NDTI, the figures we report are
weighted to reflect national patterns of practice. In each
survey, weights are associated with each visit-level record
that allows extrapolation to national estimates. These
weights account for the probability of sampling based on the
physician’s specialty and geographic area, adjusted for non-
response. Our estimates of national practice contain uncer-
tainty due to the sampling process used in each survey. In
more recent years, our annual estimates for warfarin use in
AF have 95% confidence limits of 10% for the NAMCS
estimates and 2% for the NDTI estimates. For ACEI use
in CHF, the 95% confidence limits are 8% for NAMCS
and 1.5% for NDTI. For beta-blocker and aspirin use in
CAD, the 95% confidence limits are5% for NAMCS and
1% for NDTI.
These two surveys of office-based physicians’ practices
provide similar, but distinct, sources of information on
whether physicians prescribe cardiac medications of proven
benefit. Each data source has particular strengths and
weaknesses. The short lag time in the availability of NDTI
and its larger sample size must be balanced against its
nonrandom selection of physicians and the inability to
exclude patients with contraindications to specific medica-
tions. Although NAMCS’ ability to control for contraindi-
cations is an advantage, specific medications may go unre-
ported as physicians are permitted to report only six
medications per visit record. The sample sizes associated
with NDTI allow the derivation of more statistically reliable
estimates through this data source. While neither data
source reports on adherence or unreported medication use,
these two data sources complement each other and offer the
potential for comparison of their results.
This study was carried out under Human Subjects ap-
proval by the Stanford University Institutional Review
Board.
RESULTS
Using two independent national surveys of outpatient phy-
sicians in the U.S., we noted sizable increases in the use of
cardiac medications of proven benefit. For each of the four
medications, however, the most recent data indicate that
rates of medication use remain lower than expected.
AF. From 1990 to 2000, NAMCS estimates an annual
average of 3.1 million visits for AF by patients not contra-
indicated for warfarin therapy. Warfarin anticoagulation
among these AF patients increased rapidly from 13% in
1990 to 39% in 1993. Inconsistent increases have continued
to be as high as 52% in 1997, although in 2000 the rate was
only 45%.
The NDTI estimates an annual average of 4.6 million
patient visits for AF. Similar to NAMCS, NDTI also
showed a rapid increase in warfarin use in the early 1990s,
with an increase from 12% in 1990 to 41% in 1995.
Subsequent increases have been less rapid, but consistent,
with warfarin use continuing to increase to 51% in 2002
(Fig. 1).
Figure 1. Reported warfarin use in patients with atrial fibrillation, 1990 to
2002, National Ambulatory Medical Care Survey (NAMCS) and IMS
HEALTH, National Disease and Therapeutic Index (NDTI). Data for
2002 are estimated (E) from data for January 2002 through March 2002.
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CHF. Estimates from NAMCS suggest an annual average
of 7.5 million patient visits for CHF. Among these visits,
ACEI utilization increased from 18% in 1990, to 28% in
1994, to 41% in 1999, but with a plateau effect between
1994 and 1997. We observed a sudden drop in ACEI use to
28% in 2000. The NDTI provides data on an extrapolated
estimate of 8.4 million annual encounters for all patients
with CHF. For these CHF patients, NDTI data suggests an
initial increase in ACEI use from 24% in 1992 to 34% in
1992, followed by a fluctuating plateau with gradual increase
to 38% in 2002 (Fig. 2).
CAD. The NAMCS estimates 15.8 million annual visits
by patients with CAD, without contraindications to beta-
blockers. The NAMCS indicates a fluctuating trend to-
wards increasing beta-blocker use from 14% in 1990, to 23%
in 1992, to 32% in 2000. The NDTI provides data on an
extrapolated estimate of 18.4 million annual encounters for
all patients with CAD. The NDTI shows a pattern of
steadily increasing beta-blocker use from 19% in 1991, to
26% in 1996, to 45% by 2001 (Fig. 3).
With an annual average of 15.3 million visits by CAD
patients without contraindications to aspirin, NAMCS
showed increasing aspirin use from 20% in 1990 to 32% in
1995, but then unchanged or even declining use in subse-
quent years, with 26% in 1999. In NDTI, aspirin use
increased more consistently from 14% in 1990, to 30% in
1996, to 44% in 2002 (Fig. 4).
COMMENT
Using two independent representative samples of visits to
office-based physicians in the U.S., we have found that
physicians utilize cardiac medication of proven benefit less
often than expected. Despite strong clinical evidence dem-
onstrating the benefit of warfarin in AF, ACEIs in CHF,
and aspirin and beta-blockers in CAD, use of these medi-
cations remains relatively low. While time trends indicate
increasing use of these medications, the rate of increase
noted has been slow. Given that more than a decade has
passed since conclusive evidence has been available demon-
strating the benefit of these medications, more rapid adop-
tion might have been expected. This pattern contrasts with
several examples of the rapid adoption of other new medi-
cation practices, for example the diffusion of selective
serotonin reuptake inhibitors for depression treatment in
the late 1980s (33), the rapid increase in antiobesity medi-
cation use in the mid-1990s (34), and the sharp rise of
calcium channel antagonists and ACEIs for hypertension
through the 1980s (35).
Warfarin use in AF has increased from 13% in 1990 to
45% in 2002. While this dramatic change indicates that
physicians have modified their practices in response to
evidence of warfarin’s benefits, it is concerning that warfarin
Figure 2. Reported angiotensin-converting enzyme inhibitor and angio-
tensin receptor blocker use in patients with congestive heart failure, 1990
to 2002, National Ambulatory Medical Care Survey (NAMCS) and IMS
HEALTH, National Disease and Therapeutic Index (NDTI). Data for
2002 are estimated (E) from data for January 2002 through March 2002.
Figure 3. Reported beta-blocker use in patients with coronary artery
disease, 1990 to 2002, National Ambulatory Medical Care Survey
(NAMCS) and IMS HEALTH, National Disease and Therapeutic Index
(NDTI). Data for 2002 are estimated (E) from data for January 2002
through March 2002.
Figure 4. Reported aspirin use in patients with coronary artery disease,
1990 to 2002, National Ambulatory Medical Care Survey (NAMCS) and
IMS HEALTH, National Disease and Therapeutic Index (NDTI). Data
for 2002 are estimated (E) from data for January 2002 through March
2002.
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use has increased only slowly over time and that current
levels of use remain below desired levels. This is similar to
trends reported in prior studies (1,9).
Similarly, ACEI use followed previously reported trends
in the treatment of CHF (5,12,36), being used in 40% of
the cases where it appeared to be an appropriate therapy.
While increases in ACEI use continue, the rate of increase
over the past decade has averaged only 2% per year in
absolute terms.
We observed the use of aspirin and beta-blockers in CAD
to be substantially lower than reported in most other studies
(3,21,37–39). One explanation may be that we focused on
all outpatients with CAD, whereas other studies have more
narrowly focused on CAD patients after acute coronary
events and/or hospitalizations. For both aspirin and beta-
blockers in CAD, there have been substantial increases in
use. Given that evidence of benefit has been available for
longer than for warfarin in AF and ACEIs in CHF, it is
notable that increasing use has been slow to occur and that
the current levels of use remain below desirable levels.
A number of factors may contribute to poor utilization
patterns noted for these medication therapies. Not all
physicians may be aware of the evidence supporting the use
of these medications. In some cases, physicians may over-
emphasize relative contraindications, particularly for beta-
blockers (40). In addition, the nature of outpatient practice
may interfere with guideline adherence, as patients and
physicians may stress acute care concerns while neglecting
preventive issues (41).
The results noted from the federally conducted NAMCS
and those noted from the privately surveyed NDTI are
remarkably similar. The cross-validation noted between
these two data sources allows an increased degree of
confidence in the reliability of our findings. National ex-
trapolation of patient encounters for each disease is greater
for NDTI than for NAMCS. This may result because
NDTI includes specific types of encounters (e.g., hospital
visits) and practice settings (hospital outpatient depart-
ments) that are not included in NAMCS, as well as the
exclusion of NAMCS patient visits with medication con-
traindications. As expected, there are greater fluctuations in
the medication use rates reported from NAMCS, reflecting
the smaller sample sizes available through NAMCS com-
pared with NDTI.
Study limitations. Several limitations of our analysis sug-
gest that care should be taken in interpreting some of our
results. Physicians participating in the NAMCS and NDTI
surveys may differ from nonparticipants in ways that are
difficult to assess. For example, NAMCS excludes physi-
cians practicing in publicly funded clinics. Patterns of
medication use in patients seen by office-based physicians
may not represent the general population of cardiac patients,
as patients seeing physicians more frequently are likely to be
overrepresented in both data sources.
Physicians and patients may underreport medications,
particularly aspirin because of its over-the-counter availabil-
ity. Therefore, our estimates of aspirin use may well repre-
sent underestimates. On the other hand, the failure of
physicians and patients to report such a critical medication
in CAD management would, nonetheless, suggest that
aspirin use is not being sufficiently emphasized by physicians
and patients.
In NAMCS, physicians are constrained to reporting a
limited number of medications: five in 1990 to 1995 and six
in 1996 to 2000. When patients are taking more than these
numbers, some medications will not be reported. This may
be a particular issue for patients with CHF, where the
number of medications used may easily exceed these limits.
This could contribute to the somewhat lower rates of
medication use noted for NAMCS compared with NDTI.
In NAMCS, contraindications to medication therapy
may not be fully reported. This suggests that we have
included some patients who were not eligible for the
medications being examined. With the NDTI data, it is not
possible to evaluate potential contraindications. As a result,
this data source may underestimate rates of medication use
in truly eligible patients. In neither NAMCS nor NDTI
have we been able to identify patients who are not taking
recommended medications because of past allergic or other
adverse reactions.
While we recognize that the use of these medications may
be influenced by a number of independent predictors such as
geographic location, gender, and race (9,12,22,23), such
predictor data were not included in this report.
Implications. Universal use of medications of proven ben-
efit in the management of AF, CHF, and CAD may be
neither attainable nor desirable. The use rates we note for
warfarin, ACEIs, beta-blockers, and aspirin are low enough,
however, to suggest that a significant burden of adverse
events in these cardiac conditions may result from under-
utilization of these medications. A substantial burden of
health care costs, morbidity, and mortality may be prevent-
able through the more thorough application of recommen-
dations concerning these medications.
The slow diffusion of these recommended practices calls
into question current mechanisms by which new medical
practices diffuse into community use. Other mechanisms
that promote more rapid adoption of recommended thera-
pies may be required. There may be a need for more
complete dissemination of clinical recommendations via
approaches other than clinical guidelines. In addition,
health care systems might be able to improve medication use
by providing feedback to physicians regarding their patterns
of medication use. Other possible solutions could include
mechanisms that supplant and augment the current system
of clinical care. These approaches might include nurse
case-management of longitudinal treatment, increased pa-
tient participation in prevention issues, and electronic med-
ical record systems that allow for both tracking of preven-
tion goals and real-time advice on patient management. The
potential public health benefits of increasing use of these
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medications may warrant substantial efforts in ensuring that
their use is optimized.
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